FULBRIGHT & JAWORSKI L.L.P.
A REGISTERED LIMITED LIABILITY PARTNERSHIP
666 FIFTH AVENUE, 31ST FLOOR
NEW YORK, NEW YORK 10103-3198
WWW.FULBRIGHT.COM

FACSIMILE TRANSMISSION

DATE: November 17, 2004 **MATTER NUMBER:** 01030 10109097

RECIPIENT(S):	FAX NO.:	PHONE NO.:
Examiner Fozia M. Hamud Art Unit 1647 Commissioner for Patents	1571-273-0884 1703-872-9306 ✓	1571-272-0884

FROM: Norman Hanson **FLOOR:** 24

PHONE: (212) 318-3168 **FAX:** (212) 318-3400

RE: U.S. Serial No. 10/026, 106
LUD 5752

NUMBER OF PAGES INCLUDING COVER PAGE:

Message:

IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL _____ AT _____ AS SOON AS POSSIBLE.

RECEIVED
CENTRAL FAX CENTER

NOV 17 2004

LUD 5752 (10109097)

CERTIFICATE OF FACSIMILE TRANSMITTAL

I hereby certify that this correspondence is being transmitted via FACSIMILE pursuant to 37 CFR 1.8 to Group 1647, Examiner Fozia M. Hamud of the Commissioner for Patent at (571) 273-0884 and (703) 872-9306 on Nov. 17, 2004.

Sheila Murtha
(Name of Transmitter) (Signature)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Jean-Christophe RENAULD et al.

US Serial No.: 10/026,106

Group Art Unit: 1647

Filing Date: December 21, 2001

Examiner: Fozia M. HAMUD

For: ISOLATED CYTOKINE RECEPTOR LICR-2

LETTER
SUBMISSION OF DECLARATION
(37 C.F.R. § 1.116)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In support of the patentability of this invention, applicants submit the accompanying declarations.

There are two declarations, but they are copies of the same declaration. The inventors are at different locations, hence the need for two.

It is requested that this material be considered in this case.

Respectfully submitted,

By _____
Norman D. Hanson
Registration No.: 30,946
FULBRIGHT & JAWORSKI L.L.P.
666 Fifth Avenue
New York, New York 10103
(212) 318-3000
(212) 318-3400 (Fax)
Attorneys for Applicant

Attachment: Letter Submission of Declaration

Received 11/16/2004 05:13 in 02:04 on line [3] for NH01030 Printed 11/16/2004 07:26 * Pg 2/7
16. NOV. 2004 10:15 212 LUDWIG INSTITUTE FULBRIGHT JAWORSKI NO. 5305 P. 2
LUDWIG INSTITUTE 3400
RECEIVED
CENTRAL FAX CENTER
NOV 17 2004

LUD 5752 (10109097)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant	:	Jean-Christophe RENAULD et al.
Serial No.	:	10/026,106
Filed		December 21, 2001
For	:	ISOLATED CYTOKINE RECEPTOR LICR-2
Art Unit	:	1647
Examiner	:	Fozia M. HAMUD

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION

The undersigned hereby declare as follows:

1. We are the correctly named inventors of the above referenced application, and are fully familiar with it.

2. We wish to elaborate on the experiments described in example 7 of this application, i.e., the ability of LICR-2 to activate STAT.

3. The cell line used in example 7 is known to express most of the STAT molecules.

4. Interleukin-29, or "IL-29", or "IFNλ-1" is also known to be involved in the activation of STAT3. See WO 02/086087.

5. We carried out experiments in which antiserum against LICR-2 was made and used. cDNA for LICR-2, as described in the application, was cloned into a vector,

RECEIVED TIME 28. OCT. 16:23

Received 11/16/2004 05:13 in 02:04 on line [3] for NH01030 Printed 11/16/2004 07:26 * Pg 3/7
16. NOV. 2004 10:15 212 LUDWIG INSTITUTE FULBRIGHT JAWORSKI NO. 5305 4 P. 3
LUDWIG INSTITUTE 3400

i.e., pEF.BOS.puro, using standard methods, and recombinant constructs were transfected into murine mastocytoma cell line P815. These cell lines were then transplanted via injection into syngenic DBA/2 mice. In a first injection, 300,000 cells were used, in a subcutaneous footpad injection, which was followed about 40 days later, with 400,000 cells, via the same mode. Two weeks later, a third injection, of 2 million cells, was administered intraperitoneally.

6. Sera were collected, 22 days after the first injection, and then just before the third injection. Standard assays established that the antisera were specific for LICR-2.

7. The antisera were then used, in luciferase assays as described in example 7 where BW5147 cells were transfected with wild type, LICR-2 receptor. The cells were stimulated with IL-29 (25 ng/ml) and luciferase production was upregulated by IL-29. In a parallel set of experiments, when the cells were preincubated with the LICR-2 antisera, no luciferase upregulation by IL-29 was seen.

8. The experiments in "7" were repeated, and the phosphorylation of STAT3 was measured, using standard assays. Phosphorylation of STAT3 is a prerequisite to its activation. No phosphorylation was observed in the presence of anti-LICR-2 serum.

9. These experiments lead to the conclusion that LICR-2 is in fact involved in STAT activation. STAT3 in particular.

RECEIVED TIME 28. OCT. 16:23

10. We hereby declare that all statements made herein of our own knowledge are true, and that all statements made on information or belief are believed to be true; and further that these statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements and the like so made may jeopardize the validity of this declaration, the subject application, or any patent issued thereon.

November 3, 2004
Date

Jean-Christophe RENAULD

Date

Helmut FICKENSCHER

November 3, 2004
Date

Laure DUMOUTIER

November 9, 2004
Date

Simon HÖR

Received 11/16/2004 05:13 in 02:04 on line [3] for NK01030 Printed 11/16/2004 07:26 * Pg 5/7

LUD 6752 (10109097)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant	:	Jean-Christophe RENAULD et al.
Serial No.	:	10/026,106
Filed		December 21, 2001
For	:	ISOLATED CYTOKINE RECEPTOR LICR-2
Art Unit	:	1647
Examiner	:	Fozia M. HAMUD

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION

The undersigned hereby declare as follows:

1. We are the correctly named inventors of the above referenced application, and are fully familiar with it.

2. We wish to elaborate on the experiments described in example 7 of this application, i.e., the ability of LICR-2 to activate STAT.

3. The cell line used in example 7 is known to express most of the STAT molecules.

4. Interleukin-29, or "IL-29", or "IFNλ-1" is also known to be involved in the activation of STAT3. See WO 02/086087.

5. We carried out experiments in which antiserum against LICR-2 was made and used. cDNA for LICR-2, as described in the application, was cloned into a vector,

RECEIVED TIME 28. OCT. 16:23

Received 11/16/2004 05:13 in 02:04 on line [3] for NH01030 Printed 11/16/2004 07:26 * Pg 6/7

i.e., pEF.BOS.puro, using standard methods, and recombinant constructs were transfected into murine mastocytoma cell line P815. These cell lines were then transplanted via injection into syngenic DBA/2 mice. In a first injection, 300,000 cells were used, in a subcutaneous footpad injection, which was followed about 40 days later, with 400,000 cells, via the same mode. Two weeks later, a third injection, of 2 million cells, was administered intraperitoneally.

6. Sera were collected, 22 days after the first injection, and then just before the third injection. Standard assays established that the antisera were specific for LICR-2.

7. The antisera were then used, in luciferase assays as described in example 7 where BW5147 cells were transfected with wild type, LICR-2 receptor. The cells were stimulated with IL-29 (25 ng/ml) and luciferase production was upregulated by IL-29. In a parallel set of experiments, when the cells were preincubated with the LICR-2 antisera, no luciferase upregulation by IL-29 was seen.

8. The experiments in "7" were repeated, and the phosphorylation of STAT3 was measured, using standard assays. Phosphorylation of STAT3 is a prerequisite to its activation. No phosphorylation was observed in the presence of anti-LICR-2 serum.

9. These experiments lead to the conclusion that LICR-2 is in fact involved in STAT activation, STAT3 in particular.

Received 11/16/2004 05:13 in 02:04 on line [3] for NH01030 Printed 11/16/2004 07:26 * Pg 7/7

10. We hereby declare that all statements made herein of our own knowledge are true, and that all statements made on information or belief are believed to be true; and further that these statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements and the like so made may jeopardize the validity of this declaration, the subject application, or any patent issued thereon.

November 3, 2004
Date

Jean-Christophe RENAULD

November 9, 2004
Date

Helmut FICKENSCHER

November 3, 2004
Date

Laure DUMOUTIER

Date

Simon HOR

RECEIVED TIME 28. OCT. 16:23